Pre-market hot trades in US stocks: Critical Metals up 10.08% pre-market; Shuttle Pharmaceuticals up 8.59% pre-market

Pre-market Hot Trades in US Stocks Critical Metals is up 10.08% in pre-market trading. Based on recent news, On January 20, Critical Metals announced the results of its 2025 drilling plan, showing stable rare earth element grades in the Tanbreez asset and the discovery of strategic metals such as gallium, hafnium, cerium, and yttrium. This result highlights Tanbreez's position as an important rare earth system, driving the stock price up. On January 17, Critical Metals announced plans to establish a rare earth processing facility in Saudi Arabia. This news has boosted market confidence in the company's future growth potential, further driving the stock price up. The rare earth industry has performed strongly recently, with increased demand for strategic metals. Shuttle Pharmaceuticals is up 8.59% in pre-market trading, with no significant news recently. The trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Top Gainers in Pre-market US Stocks INVO Fertility is up 464.99% in pre-market trading, with no significant news recently. The trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Icon Energy is up 138.66% in pre-market trading, with no significant news recently. The trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. RAPT is up 63.42% in pre-market trading. Based on recent key news: On January 20, GSK announced the acquisition of RAPT Therapeutics for $2.2 billion, driving RAPT's stock price up 63.42% in pre-market trading. GSK will acquire RAPT at a price of $58 per share, gaining global rights to its experimental food allergy drug ozureprubart. This move expands GSK's respiratory, immunology, and inflammation product lines. Source: Reuters On January 20, GSK's Chief Scientific Officer Tony Wood stated that ozureprubart is expected to be a best-in-class treatment option, providing sustained protection every 12 weeks. This drug is currently in Phase II trials, with trial data expected in 2027. Source: MarketWatch On January 20, analysts rated GSK stock as "Moderate Sell," reflecting the market's cautious attitude towards its acquisition strategy. Source: MarketWatch The biotech industry is active in mergers and acquisitions, with significant capital inflow